- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Sandoz launches first-to-file calcipotriene cream, the first generic version of Dovonex
Author(s):
Sandoz has announced the introduction of its first-to-file calcipotriene cream, the first generic version of LEO Pharma’s Dovonex 0.005 percent, which is indicated for the treatment of plaque psoriasis.
Princeton, N.J. - Sandoz has announced the introduction of its first-to-file calcipotriene cream, the first generic version of LEO Pharma’s Dovonex 0.005 percent, which is indicated for the treatment of plaque psoriasis.
According to IMS Health, U.S. sales for the branded version of calcipotriene cream were approximately $118.8 million for the 12 months ending in May 2012.
Sandoz is marketing calcipotriene in the 0.005% strength, the same strength that is marketed as Dovonex cream.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
